Full Press Release Details
("Midatech" or the "Company")
Midatech announces R&D collaboration with
Janssen on a second molecule
Midatech Pharma PLC (AIM: MTPH; Nasdaq:
MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce
an extension of its existing R&D collaboration with Janssen Pharmaceutica NV (Janssen)
originally announced on 21 July 2020.
2021 the Company announced that, using its Q-Sphera technology, it had successfully encapsulated a proprietary Janssen experimental large
molecule medicine and importantly preserved its functional integrity. The Company believes no other commercial or academic organisation
has been able to successfully deliver any such experimental medicine over extended periods using methods capable of commercial scaling.
the initial programme (MTX213), the collaboration has been extended to include another large molecule to the research performed by Midatech
for Janssen. As with the MTX213 molecule, the work will concentrate on maximizing drug loading and optimizing in vitro duration
of release for this undisclosed Janssen experimental molecule using the Midatech's Q-Sphera technology.
Dmitry Zamoryakhin, Chief Scientific Officer
"We look forward to working with Janssen
and the application of our technology specific to this new API."
announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).
For more information,
Stephen Stamp, CEO, CFO
Dmitry Zamoryakhin, CSO
Tel: +44 (0)29 2048 0180
Strand Hanson Limited
(Nominated and Financial Adviser)
James Dance / Matthew
Chandler / Rob Patrick
Tel: +44 (0)20 7409 3494
Turner Pope Investments
(TPI) Limited (Broker)
Andrew Thacker / James Pope (Corporate Broking)
Tel: +44(0)20 3657 0050
IFC Advisory Limited
(Financial PR and UK Investor Relations)
Tim Metcalfe / Graham
Tel: +44 (0)20 3934 6630
Edison Group (US Investor Relations)
Tel: +1 (860) 573 9637
Email: afactor@edisongroup.com
About Midatech Pharma
Midatech Pharma PLC (dual listed on LSE AIM: MTPH;
and NASDAQ: MTP) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The
Company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling
products that have the potential to powerfully impact the lives of patients.
The Company has developed three in-house technology
platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies
have successfully entered human use in the clinic, providing important validation of the potential for each platform:
The platform nature of the technologies offers
the potential to develop multiple drug assets rather than being reliant on a limited number of programmes. Midatech's technologies
are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. Midatech's headquarters and
R&D facility is in Cardiff, UK. For more information please visit www.midatechpharma.com
Forward-Looking Statements
Certain statements in
this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or
United States Private Securities Litigation Reform Act. All statements contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements, including, but not limited to, any payments that may be received, the
success of the research collaboration in developing novel products, the strategic review and formal sale process.
Reference should be made
to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London
Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules
and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could
cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking
statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning
Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or
the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update
or revise any forward-looking statements because of new information, future events or otherwise arising.